1 March 2022 - Commencing 1 March 2022, Lagevrio (molnupiravir) will be listed on the PBS Section 85 program as an Authority Required (Streamlined) benefit for patients with mild to moderate COVID 19 who have a high risk for developing severe disease, reducing the need for admission to hospital.

Lagevrio was provisionally approved by the TGA on 18 January 2022, for the treatment of adults with COVID-19 who do not require initiation of oxygen and who are at increased risk of progression to hospitalisation or death.

The Department is yet to provide details on:

• The PBAC submission date
• The evaluation of the submission
• The PBAC meeting date
• The PBAC outcome including the incremental cost effectiveness ratio
• Whether molnupiravir is provisionally listed on the PBS

The dispensed price for 40 x 200 mg capsules = $1,101.33 (no special pricing arrangement).

Read PBS News